|
531 |
Expression of Concern: Metabolic Response to Folate Supplementation in Overweight Women with Polycystic Ovary Syndrome: A Randomized Double‐Blind Placebo‐Controlled Clinical Trial
Enthalten in Molecular nutrition & food research Bd. 67, 2023, Nr. 17. 1 S.
|
|
|
|
532 |
Steroid Drugs as an Adjunct for Reducing the Incidence of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment Surgery: A Meta-Analysis of Randomized Controlled Studies
Enthalten in Ophthalmic research Bd. 66, 2023, Nr. 1: 599-610. 12 S.
|
|
|
|
533 |
Effect of Atropine 0.01% Eye Drops on the Difference in Refraction and Axial Length between Right and Left Eyes
Enthalten in Ophthalmic research Bd. 66, 2023, Nr. 1: 496-505. 10 S.
|
|
|
|
534 |
Tislelizumab plus Chemotherapie beim Ösophagus-Plattenepithelkarzinom
Enthalten in Zeitschrift für Gastroenterologie Bd. 61, 2023, Nr. 11: 1440-1442
|
|
|
|
535 |
Effect of a Toothpaste Containing Surface Pre-Reacted Glass-Ionomer Filler on the Remineralization of Artificial Carious Enamel Lesions in situ
Enthalten in Caries research Bd. 56, 2023, Nr. 5-6: 447-454. 8 S.
|
|
|
|
536 |
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis
Enthalten in American journal of nephrology Bd. 54, 2023, Nr. 9-10: 370-378. 9 S.
|
|
|
|
537 |
Effect of Lacticaseibacillus rhamnosus L8020 on the abundance of periodontal pathogens in individuals with intellectual disability: a randomized clinical trial
Enthalten in Quintessence international Bd. 54, 2023, Nr. 5: 372-383
|
|
|
|
538 |
Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom
Enthalten in Aktuelle Urologie Bd. 54, 2023, Nr. 03: 186-188
|
|
|
|
539 |
Effectiveness of oral premedication of meloxicam, ketorolac, dexamethasone, and ibuprofen on the success rate of inferior alveolar nerve block in patients with symptomatic irreversible pulpitis: a prospective, double-blind, randomized controlled trial
Enthalten in Quintessence international Bd. 54, 2023, Nr. 2: 92-99
|
|
|
|
540 |
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Enthalten in American journal of nephrology Bd. 53, 2023, Nr. 10: 687-700. 14 S.
|
|
Administration
